Reuters logo
BRIEF-Eleven Biotherapeutics reports Q4 loss per share $0.15
March 24, 2017 / 11:10 AM / 9 months ago

BRIEF-Eleven Biotherapeutics reports Q4 loss per share $0.15

March 24 (Reuters) - Eleven Biotherapeutics Inc:

* Eleven Biotherapeutics reports fourth quarter and full year 2016 financial results

* Q4 loss per share $0.15

* Q4 revenue $800,000 versus $600,000

* Eleven Biotherapeutics Inc- cash and cash equivalents were $25.3 million as of December 31, 2016, compared to $36.1 million as of December 31, 2015

* Eleven Biotherapeutics Inc- Eleven expects to have cash to fund research and development programs and operations into early 2018.

* Eleven Biotherapeutics - topline phase 3 data for lead drug candidate vicinium, in development for non-muscle invasive bladder cancer, expected in 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below